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Background. Data on the incidence of hepatitis C virus (HCV) infection among human immunodeficiency
virus (HIV)–infected persons are sparse. It is controversial whether and how frequently HCV is transmitted by
unprotected sexual intercourse.
Methods. We assessed the HCV seroprevalence and incidence of HCV infection in the Swiss HIV Cohort
Study between 1988 and 2004. We investigated the association of HCV seroconversion with mode of HIV ac-
quisition, sex, injection drug use (IDU), and constancy of condom use. Data on condom use or unsafe sexual
behavior were prospectively collected between 2000 and 2004.
Results. The overall seroprevalence of HCV infection was 33% among a total of 7899 eligible participants
and 90% among persons reporting IDU. We observed 104 HCV seroconversions among 3327 participants during
a total follow-up time of 16,305 person-years, corresponding to an incidence of 0.64 cases per 100 person-years.
The incidence among participants with a history of IDU was 7.4 cases per 100 person-years, compared with 0.23
cases per 100 person-years in patients without such a history ( ). In men who had sex with men (MSM)P ! .001
without a history of IDU who reported unsafe sex, the incidence was 0.7 cases per 100 person-years, compared
with 0.2 cases per 100 person-years in those not reporting unsafe sex ( ), corresponding to an incidencePp .02
rate ratio of 3.5 (95% confidence interval, 1.2–10.0). The hazard of acquiring HCV infection was elevated among
younger participants who were MSM.
Conclusions. HCV infection incidence in the Swiss HIV Cohort Study was mainly associated with IDU. In
HIV-infected MSM, HCV infection was associated with unsafe sex.
Chronic infection with hepatitis C virus (HCV) is a
major cause of morbidity and mortality in HIV-infected
persons in the era of potent antiretroviral therapy [1].
Transmission routes of HCV infection are injection
drug use (IDU) with needle sharing, occupational ex-
posure in health care workers, contaminated blood
products, transplants, use of medical and paramedical
devices, and vertical transmission. Whether and how
Received 14 February 2005; accepted 23 March 2005; electronically published
21 June 2005.
a Members of the Swiss HIV Cohort Study are listed at the end of the text.
Reprints or correspondence: Dr. Hansjakob Furrer, Div. of Infectious Diseases,
University Hospital, Inselspital PKT2B, CH-3010 Bern (hansjakob.furrer@insel.ch).
Clinical Infectious Diseases 2005; 41:395–402
 2005 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2005/4103-0020$15.00
frequently HCV is transmitted by unprotected sexual
contacts remains controversial [2].
In Switzerland, the incidence of acute hepatitis C in
the years 1992–2002 varied from 0 to 4 cases per
100,000 person-years, depending on the observed age
group, with a maximum incidence among those aged
20–30 years [3]. However, official incidences generally
underestimate true infection rates in the population,
because they depend on the completeness of case re-
porting, and because many asymptomatic cases of HCV
infection are not diagnosed.
Information on HCV prevalence in HIV-infected
persons is available in different settings. However, little
is known about the incidence of HCV infection in this
patient group, mainly because of a paucity of prospec-
tive cohorts with long term follow-up data. In the
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Women’s Interagency HIV Study, a low incidence of 0.27 in-
fections per 100 person-years was found, and most of these
infections could be attributed to IDU [4]. A high incidence of
HCV infection among injection drug users was found irre-
spective of HIV serostatus in different cohorts with incidence
rates of 8–41 cases per 100 person-years [5–9].
Data from serodiscordant, mainly heterosexual couples in-
dicate that HCV is rarely transmitted by sexual intercourse,
even in patients coinfected with HIV [10–13]. Nevertheless, it
has been suggested that HIV infection may be a cofactor for
sexual transmission of HCV [14]. Ulcerous infections of the
genital tract might facilitate HCV infection. However, only
sparse data are available on the incidence of HCV infection
among persons with high-risk sexual behavior. Although prev-
alence rates of up to 10% in men who have sex with men
(MSM) have been observed, they could be attributed mainly
to concurrent IDU [15]. In an Italian sexually transmitted dis-
ease clinic, incidence rates were found to be 1.3 and 0.9 cases
per 100 person-years [16] for MSM and heterosexual persons,
respectively. HIV-infected persons had a trend towards a higher
incidence of HCV infection. Intriguing recent reports suggest
increasing HCV infection rates in HIV-infected MSM who do
not consistently use condoms [17].
In the Swiss HIV Cohort Study (SHCS), seroprevalence of
HCV is repeatedly measured in seronegative persons, and in-
formation regarding IDU and condom use is collected every 6
months from all participants. For these reasons, we were able
to study the incidence of HCV infection in relation to sexual
behavior and drug use.
PATIENTS AND METHODS
The SHCS (available at http://www.shcs.ch) is a prospective
cohort study with ongoing enrolment of adult HIV-infected
patients [18]. Patients are followed-up in 1 of 7 study centers.
Information is collected according to standardized criteria on
structured forms at enrolment and at follow-up visits at 6-
month intervals. At these occasions, plasma from blood samples
is stored at 70C for every patient. Written informed consent
is mandatory for inclusion in the study, and the study has been
approved by all local ethical committees. All authors had full
access to all of the data in the Swiss HIV Cohort Study and
had final responsibility for the decision to submit this article
for publication.
HCV and syphilis serological testing. Routine serological
testing for HCV infection was introduced in 1998. In 1999,
serological testing was performed retrospectively on stored sam-
ples for all patients actively followed-up in the SHCS at that
time [19]. In HCV-seronegative SHCS participants, HCV se-
rological testing is performed every 2 years with a third-gen-
eration ELISA. Positive results are confirmed by immunoblot.
Additional testing for HCV infection is at the discretion of the
treating physicians.
With regard to classical sexually transmissible diseases, only
the results of serological testing for syphilis (Treponema palli-
dum hemagglutination assay, TPHA) are recorded at study in-
clusion in approximately two-thirds of the patients.
Sexual behavior and IDU. Information regarding IDU or
the participation in drug-substitution programs is collected at
entry to the cohort and at every follow-up visit. Patients who
reported to have a history of IDU at entry or reported IDU or
participation in a drug-substitution program at least once dur-
ing follow-up were classified as having a history of IDU.
The standardized questions regarding sexual behavior and
consistency of condom use were changed several times during
the past 16 years. The most recent change took place in April
2000 [20, 21]. Since then, participants reporting anal or vaginal
sexual intercourse have been asked whether they used condoms
always, sometimes, or never in either a stable partnership or
with occasional partners. Participants who reported that they
did not always use condoms were classified as having a history
of unsafe sex. Participants who chose not to answer the question
were classified as practising safer sex. A sensitivity analysis was
performed classifying those who chose not to answer as prac-
tising unsafe sex.
Patients in the different analyses. The number of patients
used for the analyses in the study differed with regard to avail-
able data. For prevalence data, all 7899 patients who were tested
for hepatitis C at entry into the study were included. For in-
cidence calculation, all 3327 patients who tested initially se-
ronegative for hepatitis C and underwent at least 1 serological
test during follow-up were included. For incidence calculation
that included data on condom use, all 3166 patients who were
seronegative in April 2000 and had at least 1 serological follow-
up test thereafter were included.
Statistical analysis. We used the SHCS database, updated
in June 2004, for analysis. For the subgroup analysis about
condom use, we used only data after 1 April 2000. Prevalence
of HCV infection was defined as the proportion of participants
with a positive serological test result out of those for whom a
test was performed.
Incidences were determined as seroconversions per 100 per-
son-years. The number of HCV seroconversions was divided
by the total time between first and last HCV test in participants
with negative HCV test results at time of enrolment. Individual
follow-up time was censored at the time of the first positive
HCV serological test result or the time of the last follow-up
that included HCV serotesting.
For definitions of 95% CIs, a Poisson distribution of the
seroconversions was assumed. Differences between subgroups
were analyzed using Poisson regression. Survival curves were
established with the Kaplan-Meier method, and survival was
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Table 1. Characteristics of and seroprevalence of hepatitis C virus
(HCV) infection among 7899 Swiss HIV Cohort Study (SHCS) participants
with 1 serological test result for HCV.
Variable
SHCS participants
with 1 serological
test result for HCV
All
With results
positive
for HCVa
No. (%) of patients 7899 (100) 2638 (33)
Age, median years (IQR)
Overall 35 (30–42)
Male patients 37 (32–43)
Female patients 33 (28–38)
Sex
Male 5451 (69) 1694 (31)
Female 2448 (31) 944 (39)
Presumed HIV transmission route or group
Heterosexual sex 2811 (36) 392 (14)
MSM 2550 (32) 108 (4)
IDU 2244 (28) 2080 (93)
Blood products 85 (1) 34 (40)
Other, unknown 209 (3) 24 (11)
History of IDU
Overall 2601 (33) 2329 (90)
With a presumed HIV transmission route
other than IDU, by route or group
Heterosexual sex 274 217 (79)
MSM 67 23 (34)
Blood products 3 3 (100)
Other or unknown 13 6 (46)
NOTE. Data are no. (%) of patients, unless otherwise specified. IQR, interquartile
range; MSM, men who have sex with men.
a Data are no. (%) of patients in the specified subgroup with results positive for HCV,
unless otherwise specified.
compared using the log-rank test. The Cox proportional haz-
ards model was used to test independent effects of explanatory
variables. Trend statistics among ordered groups were per-
formed using the nonparametric test described by Cuzick [22].
The statistical package Stata SE, version 8.2 (Stata) was used
for analysis.
RESULTS
Prevalence of HCV infection. Table 1 depicts the character-
istics of and HCV seroprevalence among the 7899 participants
for whom HCV serotesting was performed. The prevalence of
HCV infection among persons with a presumed HIV trans-
mission caused by IDU was 190%. There were 357 participants
who were classified as having a history of IDU but who were
not classified as having a presumed HIV transmission route of
IDU. The respective prevalence rates are shown in the lower
part of table 1.
Association of serological test results positive for syphillis
and HCV prevalence. In patients with a presumed sexual
mode of HIV transmission and no history of IDU, the prev-
alence of serological test results positive for syphilis was eval-
uated in both HCV-positive and HCV-negative individuals. In
the heterosexual transmission group, 5 (4.3%) of 113 HCV-
seropositive individuals and 112 (6.5%) of 1732 HCV-sero-
negative individuals had positive TPHA results ( ). In thePp .4
MSM transmission group, the respective numbers were 13
(4.7%) of 277 HCV-seropositive participants and 34 (2.3%) of
1499 HCV-seronegative participants ( ).Pp .02
Incidence of HCV infection. In 1830 (34.8%) of the 5157
participants who were initially seronegative for HCV, no se-
rological follow-up data were available, and they were therefore
excluded from incidence calculations. The excluded patients
differed epidemiologically from those with follow-up data. HIV
transmission route for the excluded patients was less likely to
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Table 2. Incidence rates of hepatitis C virus (HCV) infection among 3327 Swiss HIV Cohort Study participants
with initial serological test results negative for HCV.
Patient characteristic
No. of patients
with HCV
seroconversion
Incidence
per 100
person-years
(95% CI)
Incidence
rate ratio
(95% CI)a P
Sex
Female 32 0.79 (0.54–1.1) 1.33 (0.89–1.24) .2
Male 72 0.59 (0.46–0.74)
Heterosexual HIV acquisition in patients
without IDU, by sex
Female 6 0.17 (0.06–0.37) 0.96 (0.29–3.13) .9
Male 5 0.18 (0.06–0.42)
History of IDU
Yes 69 7.4 (5.7–9.3) 32.3 (21.5–48.5) !.001
No 35 0.23 (0.15–0.31)
Observation period for patients without IDU
Before April 2000 12 0.15 (0.08–0.27)
After April 2000 23 0.28 (0.18–0.42)
MSM without IDUb
Unsafe sex 8 0.70 (0.30–1.4) 3.45 (1.21–10.04) .02
Safe sex 6 0.20 (0.07–0.43)
NOTE. IDU, injection drug use; MSM, men who have sex with men.
a Incidence rate ratios are calculated using Poisson regression analysis
b With follow-up after April 2000.
be sex between MSM (41% vs. 49%) and more likely to be
heterosexual sex (52% vs. 43%); correspondingly, excluded par-
ticipants were more likely than others to be female (31% vs.
23%), but there was no difference in the age distribution.
In the remaining 3327 participants with follow-up data, we
observed a total of 104 cases of HCV seroconversion during a
total observation time of 16,305 person-years. The median ob-
servation time was 4.4 years (interquartile range, 2.9–6.2 years).
This resulted in an overall incidence of 0.64 cases per 100
person-years (95% CI, 0.52–0.77 cases per 100 person-years).
The incidences of HCV in different subgroups are shown in
table 2 and figure 1A. A history of IDU was associated with a
∼30-fold increase in risk of acquiring HCV infection.
HCV seroconversion and ongoing IDU. Among the par-
ticipants with a history of IDU, the incidences differed ac-
cording to the reported mode of drug use during the follow-
up period. The incidences in the respective groups were 5.5
cases per 100 person-years (95% CI, 3.6–7.8 cases per 100
person-years) in 549 participants who denied IDU or partici-
pation in a drug-substitution program during follow-up, 5.4
cases per 100 person-years (95% CI, 2.4–12.5 cases per 100
person-years) in 93 participants in a drug-substitution program
with no IDU, 13.2 cases per 100 person-years (95% CI, 8.1–
20.5 cases per 100 person-years) in 151 participants in a drug-
substitution program with concurrent IDU, and 9.7 cases per
100 person-years (95% CI, 5.3–16.2 cases per 100 person-years)
in 145 individuals who did not participate in a drug-substi-
tution program but reported IDU during follow-up. In a mul-
tivariate Poisson regression analysis involving patients with a
history of IDU, incidence rate ratios were 2.0 (95% CI, 1.2–
3.3) for patients with continuing IDU ( ) and 1.2 (95%Pp .01
CI, 0.7– 2.1) for patients with participation in a drug-substi-
tution program ( ) during follow-up.Pp .5
HCV seroconversion and sexual behavior. A total of 3166
participants who were HCV seronegative at the first visit after
1 April 2000 contributed to the analysis of the association of
HCV incidence with unsafe sex. The presumed HIV transmis-
sion route or group was heterosexual sex in 1383 participants
(44%), MSM in 1571 (50%), IDU in 74 (2%), and other or
unknown in 138 (4%). IDU was reported by 36 (2.6%) of the
heterosexual patients and 29 (1.8%) of the MSM; these par-
ticipants were excluded from the analysis of the association of
HCV incidence with unsafe sex. In the remaining heterosexual
transmission group, 752 (56%) were women. Unsafe sex was
reported by 401 (30%) of the heterosexual transmission group
(25% by men and 34% by women) and by 414 (27%) in the
MSM transmission group. In the youngest quartile of age
(younger than 32.5 years) of MSM participants, unsafe sex was
reported by 36%. This proportion was significantly smaller in
the older age groups: 28%, 24%, and 20% in the second, third,
and fourth quartile of age respectively ( for trend).P ! .001
We observed an apparently higher incidence of HCV infec-
tion in recent years among patients without a history of IDU
(table 2). However, this finding should be interpreted cau-
Figure 1. Kaplan-Meier estimates of probability of remaining uninfected with hepatitis C virus (HCV) in patients with initial serological test results
negative for HCV according to presumed HIV transmission route (A), according to reported unsafe sex (B) among men who have sex with men (MSM),
and in the MSM group according to quartiles of age (C). In panel A, all patients with a presumed sexual HIV transmission route but with a history
of injection drug use (IDU) were excluded from analysis. In the log rank test, there was a highly significant difference between the IDU group and
the sexual transmission route groups ( , by the log-rank test), whereas no difference was found between the heterosexual transmission routeP ! .0001
(HET) group and the MSM group ( , by the log rank test). In panel B, all patients with a history of IDU were excluded from analysis. ParticipantsPp .6
reporting unsafe sex had a greater probability of acquiring HCV infection ( , by the log rank test). In panel C, all patients with a history ofPp .01
IDU were excluded from analysis. There was a significant trend towards a higher risk of acquiring HCV infection in younger participants ( ,Pp .02
by the log rank test).
400 • CID 2005:41 (1 August) • HIV/AIDS
Table 3. Cox proportional hazards models for acquiring hepatitis C virus
(HCV) infection for Swiss HIV Cohort Study participants with follow-up after
April 2000 and without a history of injection drug use (IDU).
Subpopulation, parameter
Adjusted
hazard ratio
(95% CI) P
All participants without history of IDU
Female 0.4 (0.1–1.6) .18
Unsafe sex 3.4 (1.5–7.8) .004
Heterosexual HIV transmission route 0.9 (0.11–7.0) .9
MSM 0.9 (0.11–6.7) .9
Participants with heterosexual HIV transmission mode
Female 0.6 (0.13–2.6) .5
Unsafe sex 3.0 (0.74–12.2) .1
Age per quartile increase 1.7 (0.8–3.5) .2
Participants with MSM HIV transmission mode
Unsafe sex 3.0 (1.03–8.8) .04
Age per quartile increase 0.6 (0.37–1.06) .08
NOTE. The hazard ratio is adjusted for all variables in the table. MSM, men who have
sex with men.
a Statistically significant.
tiously, because serological analyses were partly performed ret-
rospectively before April 2000.
In participants with presumed HIV transmission by MSM
contacts, the incidence of HCV infection was significantly
higher for those who reported unsafe sex than for those who
did not (table 2). The association of unsafe sex and HCV ac-
quisition was further analyzed using Cox proportional hazards
models in participants without a history of IDU and presumed
sexual transmission of HIV (table 3). There was a statistically
significant association between reporting of unsafe sex and the
hazard of HCV seroconversion. This association was significant
in the participants with HIV transmission by MSM (figure 1B),
but it did not reach statistical significance in participants with
heterosexual transmission.
In addition, younger MSM participants had a higher risk of
HCV seroconversion. This association was statistically signifi-
cant in the univariate survival analysis (figure 1C) and remained
a trend in the Cox proportional hazards model (table 3).
Given the association of HCV prevalence and syphilis prev-
alence in MSM participants, we introduced the results of se-
rological testing for syphilis at baseline into the Cox propor-
tional hazards model of HCV infection. Because information
about serological testing for syphilis at baseline was not avail-
able for one-third of the patients, this model had less power
than did the former model. There was a significant association
of a positive TPHA result at baseline and the risk of HCV
seroconversion, with an adjusted hazard ratio of 4.6 (95% CI,
1.2–17.4; ); however, in this model, the parameter ofPp .03
unsafe sex was not significantly associated with the risk of HCV
seroconversion (adjusted hazard ratio, 2.0; 95% CI, 0.6–6.9;
).Pp .3
Sensitivity analysis. A sensitivity analysis classifying those
who chose not to answer the question about condom use as
practising unsafe sex was performed. All of the significant as-
sociations in table 2, as well as the log rank statistics of figures
1A, 1B, and 1C, remained. However, for the association in the
multivariable Cox proportional hazards model of MSM (table
3), the adjusted hazard ratio for unsafe sex was 2.8 (95% CI,
0.97–8.2; ), whereas the estimate for quartiles of agePp .056
remained in the same range.
DISCUSSION
Because chronic hepatitis C is a major cause of morbidity and
mortality in persons with HIV-HCV coinfection in the era of
potent antiretroviral therapy [1], every measure should be taken
to prevent HCV infection. Our analysis shows continuing HCV
infection in a nationwide cohort of adult persons with HIV
infection in Switzerland. HCV incidence is highest in persons
with a history of IDU, with incidence rates of 5–13 cases per
100 person-years. HCV infections occur also in persons without
reported IDU, although at an incidence rate 30 times lower.
Intriguingly, HCV infection is associated with inconsistent con-
dom use in MSM in our cohort.
Despite well-functioning drug-substitution and harm-
reduction programs in Switzerland [23–25], IDU remains the
major risk factor for acquiring HCV infection in our cohort.
This is reflected by the high prevalence of HCV infection
(190%) found in HIV-infected persons with a history of IDU
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entering the SHCS. Despite regular care in specialized centers,
the incidence of HCV infection among participants with con-
tinuing IDU remains in the range of 10 cases per 100 person-
years. More emphasis should therefore be given to informing
patients about this risk, allowing injection drug users safe
injection procedures, and establishing opiate-substitution
programs.
Among persons without a history of IDU, the incidence of
HCV infection is much lower. The transmission route of these
infections is unclear. Unsafe medical procedures are unlikely
to have a major impact in established health care settings, but
paramedical and nonmedical interventions, such as acupunc-
ture or tattooing [26], remain a possible route of transmission.
The possibility of HCV transmission by sharing materials used
for intranasal cocaine use remains controversial [27–29].
HCV infections in serodiscordant couples are rarely ob-
served, at least not in heterosexual couples [10, 12, 30]. Many
experts therefore conclude that sexual transmission of HCV is
of little importance. Nevertheless, concurrent genital ulcers
caused by genital herpes simplex or syphilis might facilitate
transmission of HCV if condoms are not consistently used [31].
In some studies, HCV prevalence was associated with increased
numbers of sexual partners and intercourses, especially among
MSM [32–34]; others, however, could not find such an asso-
ciation [35]. These contradictory results can be explained by
differences in study design, because most study were cross-
sectional analyses. In addition, immunodeficiency associated
with concurrent HIV infection may influence the threshold of
HCV infectivity.
Although our findings were based on a small number of
seroconversions, we found a statistically significant association
between reporting unsafe sex and HCV infection among MSM
in recent years. We conclude that inconsistent condom use
bears a small but significant risk for HCV infection in unpro-
tected male homosexual contacts. Of note, there are recent
reports of small epidemics of HCV infection in the gay com-
munity [17]. We observed a significant trend towards an in-
creased risk of HCV seroconversion in younger MSM. If HCV
is sexually transmissible, this finding is in concordance with a
recent report about a lower adherence to safer sex in younger
participants in the SHCS [21] and with the higher proportion
of younger MSM participants in this analysis reporting unsafe
sex. The association between serological test results positive for
syphilis and the incidence of HCV infection in the MSM pop-
ulation further points towards possible sexual transmission of
HCV infection.
With regard to heterosexual relationships without consistent
condom use, our data do not show a statistically significant
increased risk of HCV infection; however, the point estimate
of the hazard ratio for unsafe sex was 3.0. This clearly does
not allow one to exclude such a risk.
To our knowledge, this is the first report of an association
of unsafe sex with an increased incidence of HCV infection in
HIV-infected MSM that was determined on the basis of pro-
spective longitudinal cohort data that included regular HCV
testing and reports about condom use and IDU. Limitations
of our analyses are that we cannot totally exclude confounding,
because we did not ask for data on other risks for acquisition
of HCV infection. One might hypothesize that sexual risk be-
havior might be a surrogate for other risk behavior, such as
tattooing or intranasal drug use. In addition, data about sexual
behavior and IDU are based on self-reporting. Self-reporting
of behaviors considered to be irresponsible may be less con-
sistent than other methods of reporting. This could favor un-
derreporting of IDU in MSM. On the other hand, if HCV really
is sexually transmissible, underreporting of unsafe sex would
weaken the association described above. Another potential lim-
itation is that we cannot rule out the possibility of seroreversion
of the results of serological testing for HCV from negative to
positive in patients previously infected with HCV who had lost
anti-HCV antibodies because of severe HIV-induced immu-
nodeficiency [36, 37].
In conclusion, data of the large, prospective SHCS indicate
that unsafe sexual behavior among MSM is associated with new
acquisition of HCV infection and that HCV seroconversion
continues to occur among IDU, even though needle exchange
programs are available in Switzerland. Thus, physicians caring
for HIV-infected persons need to emphasize the prevention of
HCV infection among their patients with continuing IDU and
motivate MSM to practice safe sex because of the additional
risk of transmitting and acquiring HCV infection.
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